ECSP22092185A - Anticuerpos anti-pd-1 - Google Patents

Anticuerpos anti-pd-1

Info

Publication number
ECSP22092185A
ECSP22092185A ECSENADI202292185A ECDI202292185A ECSP22092185A EC SP22092185 A ECSP22092185 A EC SP22092185A EC SENADI202292185 A ECSENADI202292185 A EC SENADI202292185A EC DI202292185 A ECDI202292185 A EC DI202292185A EC SP22092185 A ECSP22092185 A EC SP22092185A
Authority
EC
Ecuador
Prior art keywords
antibodies
antigen
therapeutic
compositions
cell death
Prior art date
Application number
ECSENADI202292185A
Other languages
English (en)
Inventor
David A Blair
Della M White
Helen Haixia Wu
Joseph A Mozdzierz
Fei Han
Pankaj Gupta
Abdulsalam Shaaban
Nicole K Garaffa
Miguel E Moreno-Garcia
Mouhamadou Lamine Mbow
Kerry L M Ralph
Dongmei Liu
Timothy Karlak
Guangwei Yang
Priyanka Nair-Gupta
Ivo Lorenz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22092185A publication Critical patent/ECSP22092185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a nuevos anticuerpos anti-PD-1 (muerte celular programada 1) y fragmentos de unión al antígeno de los mismos para métodos terapéuticos y de diagnóstico y composiciones que los utilizan.
ECSENADI202292185A 2020-05-26 2022-12-09 Anticuerpos anti-pd-1 ECSP22092185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063029962P 2020-05-26 2020-05-26
US202063039686P 2020-06-16 2020-06-16
PCT/US2021/033823 WO2021242663A1 (en) 2020-05-26 2021-05-24 Anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
ECSP22092185A true ECSP22092185A (es) 2023-01-31

Family

ID=76808128

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202292185A ECSP22092185A (es) 2020-05-26 2022-12-09 Anticuerpos anti-pd-1

Country Status (18)

Country Link
US (1) US20210380696A1 (es)
EP (1) EP4157876A1 (es)
JP (1) JP2023528778A (es)
KR (1) KR20230015997A (es)
CN (1) CN115956087A (es)
AU (1) AU2021280232A1 (es)
BR (1) BR112022023989A2 (es)
CA (1) CA3181776A1 (es)
CL (1) CL2022003304A1 (es)
CO (1) CO2022018416A2 (es)
CR (1) CR20220596A (es)
DO (1) DOP2022000264A (es)
EC (1) ECSP22092185A (es)
IL (1) IL298431A (es)
MX (1) MX2022014974A (es)
PE (1) PE20231076A1 (es)
TW (1) TW202216765A (es)
WO (1) WO2021242663A1 (es)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
EP3153583B1 (en) 2010-12-31 2021-10-20 BioAtla, Inc. Express humanization of antibodies
AR106184A1 (es) 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
US11299751B2 (en) * 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2018282094A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
TWI708787B (zh) 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1促效劑抗體及其用途
BR112021024507A2 (pt) 2019-06-05 2022-03-08 Anaptysbio Inc Agonista de pd-1 e método de uso do mesmo

Also Published As

Publication number Publication date
CA3181776A1 (en) 2021-12-02
KR20230015997A (ko) 2023-01-31
CN115956087A (zh) 2023-04-11
DOP2022000264A (es) 2023-01-31
TW202216765A (zh) 2022-05-01
US20210380696A1 (en) 2021-12-09
JP2023528778A (ja) 2023-07-06
PE20231076A1 (es) 2023-07-17
IL298431A (en) 2023-01-01
EP4157876A1 (en) 2023-04-05
WO2021242663A1 (en) 2021-12-02
BR112022023989A2 (pt) 2023-02-07
CO2022018416A2 (es) 2022-12-30
MX2022014974A (es) 2023-01-11
CL2022003304A1 (es) 2023-04-14
CR20220596A (es) 2023-01-23
AU2021280232A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
ECSP099656A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
AR121599A1 (es) Anticuerpos
CO2023017156A2 (es) Anticuerpos anti-sirp-alfa
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
CL2022001554A1 (es) Anticuerpos anti-mertk y métodos de uso de los mismos
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
CO2022000832A2 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
DOP2022000295A (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
CO2021007882A2 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CO2022018807A2 (es) Captadores de células inmunitarias biespecíficas con especificidad de unión para hla-g y otro antígeno
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CL2021002603A1 (es) Anti–cd25 para el agotamiento de células específicas de tumores (divisional de la solicitud no. 202002340)
CO2022018416A2 (es) Anticuerpos anti-pd-1
CL2023000084A1 (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
ECSP22004680A (es) Anticuerpos anti-angpt2
CO2023015859A2 (es) Anticuerpos para tratar alfa-sinucleinopatías
AR115987A1 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
AR122660A2 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2022000404A2 (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden